Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01177 SINO BIOPHARM
RTNominal up3.020 +0.010 (+0.332%)
Others

10/10/2019 17:28

Sino Biopharm (01177) gets drug registration approval

[ET Net News Agency, 10 October 2019] Sino Biopharmaceutical Limited (01177) said
Azacitidine for injection, an anticancer drug developed by Chia Tai Tianqing
Pharmaceutical Group Co., Ltd., a subsidiary of the company, has obtained approval for
drug registration granted by the National Medical Products Administration of the People's
Republic of China.
Such product is a Chemicals Category 3 drug and is the first domestic generic drug that
has completed the bioequivalence study in accordance with the draft Azacitidine Guide
issued by the United States Food and Drug Administration and passed the confirmatory
clinical trial.
Azacitidine is a cytosine nucleoside analog, being a demethylating drug with a dual
mechanism of action and currently the only clinically proven drug to improve overall
survival. (RC)

Remark: Real time quote last updated: 28/03/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.